Pretty much price vs risk - as you say I've been sceptical in the past and still retain a fairly healthy scepticism.
But I've always had a soft spot for MSB, I knew Silviu from his time at Columbia, was an investor in the IPO and it made me a lot of money with the Cephalon deal, so I've continued to follow it with interest in the years since. I've dipped my toes back in a couple of times since then with mixed results, who knows what this time will bring. But I think the upside is worth the risk at this price and at this stage in clinical development.
And if I'm wrong, I could do with some tax losses!
Ann: Update on BLA for Graft Versus Host Disease, page-556
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.23 |
Change
-0.030(2.38%) |
Mkt cap ! $1.404B | |||
| Open | High | Low | Value | Volume |
| $1.26 | $1.30 | $1.22 | $10.22M | 8.142M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 11752 | $1.23 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.23 | 67205 | 1 |
View Market Depth
| Last trade - 16.10pm 29/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.23 |
Change
-0.030 ( 3.67 %) |
||||
| Open | High | Low | Volume | ||
| $1.26 | $1.29 | $1.22 | 1670014 | ||
| Last updated 15.59pm 29/05/2024 ? | |||||
| MSB (ASX) Chart |